Cargando…
MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas
OBJECTIVE: The antitumor effects of anti-PD-1 antibody against mismatch repair deficiency (MMR-D)-associated cancers have been reported. MMR-D is found in approximately 20%–30% of endometrial carcinomas (ECs) and frequently occurs due to MLH1 promoter hypermethylation (MLH1-PHM). ECs with MLH1-PHM a...
Autores principales: | Kaneko, Enami, Sato, Naoki, Sugawara, Tae, Noto, Aya, Takahashi, Kazue, Makino, Kenichi, Terada, Yukihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550932/ https://www.ncbi.nlm.nih.gov/pubmed/34431253 http://dx.doi.org/10.3802/jgo.2021.32.e79 |
Ejemplares similares
-
Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients
por: Kato, Aya, et al.
Publicado: (2016) -
Cesarean scar caseating granuloma: a case of vesicouterine fistula 30 years after cesarean section
por: Sato, Toshiharu, et al.
Publicado: (2016) -
Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review
por: Yokoyama, Takanori, et al.
Publicado: (2018) -
Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer
por: Loukovaara, Mikko, et al.
Publicado: (2021) -
Mlh2 Is an Accessory Factor for DNA Mismatch Repair in Saccharomyces cerevisiae
por: Campbell, Christopher S., et al.
Publicado: (2014)